Overview
Study information
| Network: | CAVD |
| Grant Affiliation: | Pantaleo: Poxvirus-Based Vaccine Development |
| Strategy: | Combo: DNA & vector vaccines |
| Study Type: | Phase I/II |
| Species: | Human |
| Stage: | Assays Completed |
| Study Start Date: | 2010-08-04 |
| Study Made Public: | 2013-08-16 |
Title
A phase I/II trial to compare the immunogenicity and safety of 3 DNA-C prime followed by 1 NYVAC-C boost to 2 DNA-C prime followed by 2 NYVAC-C boost
Description
CAVD 256 (EV03/ANRSVAC20) is Phase I/II study to compare the immunogenicity and safety of 3 DNA-C prime followed by 1 NYVAC-C boost to 2 DNA-C prime followed by 2 NYVAC-C boost.
Sign in to see full information about this study and to download study data.
Products
NYVAC-C (vP2010) DNA-CIntegrated data
BAMA, NAb
Non-integrated data
No non-integrated data is available for this study.